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Background: Acute coronary syndrome (ACS) is highly prevalent in Korea and is the third-leading cause of death in
Korea; however, the economic cost of ACS on Korean society has not been investigated. This study examined the
economic effect of ACS on the Korean population during the period 2004 to 2009.
Methods: The analysis used the cost of illness (COI) framework. Data on direct medical costs, direct non-medical
costs, and productivity loss related to ACS morbidity and mortality were included. The Korean National Health
Insurance Corporation’s claim database was used to obtain data on annual healthcare utilization and expenditures
for the entire South Korean population. By using a data mining technique, we identified healthcare claims with
ACS-related disease codes. Costs were estimated by using a macro-costing method.
Results: In 2009, the prevalence of ACS in Korea was 6.4 persons per 1,000 population members and the associated
mortality rate was 20.2 persons per 100,000 population members. The total cost of ACS in 2009 was USD 918.2
million. Of the total, direct medical cost was USD 425.3 million, direct non-medical cost was USD 11.4 million,
and cost associated with morbidity and mortality was USD 481.5 million.
Conclusions: The results show that the total cost of ACS to the Korean society is high. Early and effective
management of ACS is required to reduce ACS-associated mortality and morbidity. We suggest that further
research be undertaken to determine ways to reduce the economic effects of ACS and its treatment.
Keywords: Acute coronary syndrome, Cost of disease, Unstable angina, Myocardial infarction,
Ischemic heart diseaseBackground
Acute coronary syndrome (ACS), which includes un-
stable angina (UA), non-ST-segment elevation myocar-
dial infarction (MI) and ST-segment elevation MI, is
highly prevalent in Korea and is the third-leading cause
of death in South Korea [1]. Moreover, ACS is the most
common condition related to ischemic heart disease in
the West, and it is the major condition associated with
heart disease requiring hospitalization [2-4]. According
to the Korean National Statistical Office, the current
level of morbidity and mortality associated with ACS has
increased markedly from the level of 10 years ago [1]. In
a previous study, the treatment cost associated with
cardiovascular disease in Korea was USD 1.38 billion in* Correspondence: current5@snu.ac.kr
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reproduction in any medium, provided the or2001 and USD 2.25 billion in 2005 while the COI was
USD 5.13 billion in 2001 and USD 5.89 billion in 2005
[5]. Since the aging index in Korea is estimated to in-
crease from 67.7% in 2010 to 213.8% in 2030 [1], cardio-
vascular disease is expected to increase steadily for
metabolic syndrome according to aging [6]. Thus, the
prevalence of ACS and its associated costs are also
expected to increase markedly. However, the economic
effect of ACS on the Korean society has not been previ-
ously reported. In this study, we report on the economic
burden of ACS in Korea over between 2004 and 2009.Methods
Study design
This retrospective study analyzed data from the Korean
National Health Insurance Corporation’s (NHI) claims
database that included medical claim information for the
entire South Korean population (approximately 49 million. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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expenditures as well as financial and reimbursement status.
This large, longitudinal database provides integrated enroll-
ment, medical, and prescription data for the entire Korean
population, which can be stratified by age and gender
(Figure 1).
Institutional review board and ethic committee approvals
were not required for this study.
Patient identification
The study population included patients with UA or MI
who were discharged from hospitals from 2004 to 2009.
Patients enrolled included those with medical claims
with the International Statistical Classification of Dis-
eases and Related Health Problems 10th Revision (ICD-
10) codes for ACS and included I20.0 (UA), I21 (acute
MI), I22 (subsequent MI), I23 (certain current complica-
tion following acute MI), I25.0 (atherosclerotic cardio-
vascular disease, sp described), and I25.1 (atherosclerotic
heart disease) of MI. Codes I25.0 and I25.1 are chronic
diseases and examination and treatments such as creat-
ine kinase muscle-brain (CK-MB), troponin, coronary ar-
tery bypass graft (CABG) and percutaneous coronary
intervention (PCI) for MI patients are frequently claimed
with those codes at several medical institutions in Korea;
thus, the positive rate of MI associated with those codes
was high in a previous study [7]. To avoid underestima-
tion of MI prevalence and to allow comparison with pre-
vious results, our study included codes I25.0 and I25.1.
Cost
The analysis used a COI framework and included direct
medical costs, direct non-medical costs, and indirectFigure 1 Process of extracting ACS data from the national health insucosts such as productivity loss from ACS-related mor-
bidity and mortality [8,9]. Our estimate of total societal
cost (SC), which included direct costs (DC) and indirect
costs (IDC), was developed by using a macro-costing
method.
The DC incurred when treating ACS included direct
medical costs (MC), such as hospitalization and out-
patient costs, and direct non-medical costs (NMC), such
as transportation and caregiver costs.
The main payment system for healthcare in Korea is
based upon a fee-for-service (FFS). All MC are deter-
mined within that FFS system. We used the NHI claims
database to determine NHI payments and a national sur-
vey report [10,11] to determine out-of-pocket (OOP)
payments. The ACS-related NHI payment was obtained
by summing payments for each ICD code extracted from
the NHI database. To determine OOP payments, we ap-
plied a previously reported ratio of OOP payment to
NHI payment for ACS [11]. Total MC included NHI








InNHIij =NHI payment for hospitalization expendi-
tures, OutNHIij =NHI payment for outpatient expendi-
tures, OOP = out-of-pocket payment, i = 0,1,…, n (age),
and j = 1 or 2 (gender).
The NMC included transportation expenditures when
patients visited a medical center and caregiver expendi-
tures during hospitalization. Since a variety of transpor-
tation types were used by patients, we estimatedrance database.
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costs reported in a 2007 Korean national health and nu-
trition survey [12], adjusted by the 2004 and 2009
changes in the Korean transportation price index. In our
estimation of caregiver costs, we excluded costs related
to informal care provided by relatives because of insuf-
ficient data on the characteristics of the relatives. Care-
giver cost was calculated by using the average caregiver
costs reported in the 2007 Korean national health and
nutrition survey [12], adjusted by the other-medical-
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InOij = number of hospitalization visits, OutOij = num-
ber of outpatient visits, M = transportation costs (based
on round-trip transport), InNij = length of hospitali-
zation, I = caregiver costs per day, i = 0,1,…,n (age), and
j = 1 or 2 (gender).
The Human Capital Approach [13] was used to esti-
mate the IDC of lost wages (LW) and lost future income
(LFI) due to morbidity. To estimate the productivity loss
due to morbidity, non-productivity days were calculated
by summing hospitalization days and one-third of the
number of outpatient days, as previously described [5].
Since outpatient-related productivity loss is less than
hospitalization-related loss, we reduced outpatient days
by two-thirds of the non-productivity rate reported pre-
viously [5]. After determining the non-productivity days,
we estimated the productivity loss due to morbidity by
multiplying the non-productivity days by the labor force
participation rate, the employment rate, and by the
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InNij = length of hospitalization, pij = labor force par-
ticipation rate, eij = employment rate, yij = average daily
earning, OutNij = outpatient visiting days, i = 0,1,…,n
(age), and j = 1 or 2 (gender).
The lost income due to illness (LFI) was estimated
from death-related statistical data in the Korean Na-
tional Statistics Office database [1]. The calculation of
LFI converted future income of the deceased patient into
a present value. To estimate LFI, we assumed no pro-
duction activity for patients aged under 15 years and
over 65 years. Data on patients that died due to ACS
were used, by multiplying the period, average earnings,
labor force participation rate, and employment rateaccording to age and gender (equation 4), to calculate
the future period of production activity and to estimate
lost income. Based on a previous study, the discount rate
(r) for converting future income to present value was 0%
[15]. Future income was increased by the previously
reported wage growth rate. However, the average wage
growth rate for the past 4–5 years ranged between 4.8%
and 5.4%, which was similar to the reported 5% discount
rate in the health care sector; therefore, we applied a dis-
count rate r of zero. Equation 4 presents the calculation
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Fij = number of deaths, Yj
t+τ = average expected income
in year t + τ (t = age at death and τ = life year), pij = labor
force participation rate, eij = employment rate, r = dis-
count rate, i = 0,1,…,n (age), and j = 1 or 2 (gender)
Results
Epidemiology
The number of patients with ACS increased during the
six study years. In 2004, there were 217,297 patients
with a primary or secondary discharge diagnosis of ACS
discharged from hospitals in South Korea. Increasing an-
nually, the number of patients with ACS was 309,384 in
2009. Among the ACS patients, approximately 60% were
male with similar proportions of males in each year from
2004 to 2009. The prevalence of ACS increased with age
and, in 2009, approximately 64.1% of the ACS patients
were 60 years of age or older. In 2004, the number of
patients with MI was 119,775, representing 55.1% of the
patients with ACS. The number of MI patients increased
between the years 2004 and 2007 and then decreased
until 2009. The number of MI patients was 148,989 in
2009, lower than the number of UA patients. The preva-
lence of ACS was 6.4 persons per 1,000 population
members in 2009, an increase of 42.4% from the ACS
prevalence in 2004 of 4.5 persons per 1,000 population
members (Table 1).
In 2004, the number ACS patient deaths was 9,863.
That number increased annually and was 11,236 per-
sons in 2006. However, since 2006, the number of
ACS-related deaths has decreased: 10,659 people in
2007, 9,929 in 2008, and 9,831 in 2009. The mortality
rate associated with ACS was 20.5 persons per 100,000
population members in 2004. That rate increased from
2004 to 2006 and then decreased until 2009. Deaths re-
lated to UA represented 2.3% of the ACS deaths while
death due to MI represented 97.7% of all ACS deaths
in 2009 (Table 1).
Table 1 Epidemiology of ACS in South Korea from 2004 to 2009
2004 2005 2006 2007 2008 2009
Prevalence
Number of patients 217,297 238,517 257,889 283,829 291,088 309,384
Prevalence per 1000 population 4.5 5.0 5.3 5.9 6.0 6.4
Gender (%)
Male 130,004 143,556 157,692 173,582 179,530 192,317
% of male 59.8% 60.2% 61.1% 61.2% 61.7% 62.2%
Age
Over 60 128,528 143,745 155,569 174,423 183,408 198,212
% of over 60 59.1% 60.3% 60.3% 61.5% 63.0% 64.1%
Diagnosis
UA 97,522 108,926 121,625 140,008 148,491 160,395
MI 119,775 129,591 136,264 143,821 142,597 148,989
Mortality
Number of death 9,863 9,935 11,236 10,659 9,929 9,831
Mortality per 100 000 population 20.5 20.6 23.3 22.0 20.4 20.2
Diagnosis
UA 227 227 240 280 225 252
MI 9,636 9,708 10,996 10,379 9,704 9,579
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The total number of hospital visits due to ACS increased
every year from 494,226 visits in 2004 to 786,827 visits
in 2009. The hospital visits for outpatients increased
sharply compared to those for inpatients and the
outpatient-to-inpatient ratio was 9.7:1 in 2009 compared
to 6.9:1 in 2004. The number of ACS-related inpatient
days increased from 449,660 days in 2004 to 487,323 days
in 2009. The number of inpatient days per visit decreased
gradually from 7.18 days in 2004 to 6.62 days in 2009
(Table 2).
Societal cost
The ACS-related NHI expenditures increased by 30.2%
over the six study years from USD 208.7 million in 2004
to USD 334.3 million in 2009. The NHI payments for
male ACS patients increased from USD 134.3 million in
2004 to USD 220.9 million in 2009 and were higher thanTable 2 Medical utilization due to ACS from 2004 to 2009
2004 2005




Total inpatient days 449,660 457,618
Inpatient days per case 7.18 6.99those for females. The highest NHI expenditure by age
group was USD 133.0 million, which occurred in 2009
for patients aged over 60 years. Based on treatment type,
NHI hospitalization expenditures ranged between 83.4%
and 84.1% of the total NHI costs, a percentage range
that was approximately five times higher than that for
outpatient care expenditures. Based on disease group,
NHI payments associated with MI were USD 132.0 mil-
lion in 2004 and USD 208.1 million in 2009, repre-
senting between 60.7% and 63.3% of the total NHI
expenditures. The largest NHI expenditure proportion
among the various medical institution types was 50.0%,
paid to tertiary hospitals. By payment categories, the
proportion expended for procedures and operations
ranged between 33.6% and 34.0%, which was the highest
level, followed by 27.1% to 27.4% expended for radiog-
raphy, 11.4% to 12.1% expended for pharmaceuticals,
and 10.5% to 10.7% for examinations (Table 3).2006 2007 2008 2009
597,739 695,024 733,313 786,827
530,747 663,056 663,056 713,139
66,971 73,124 70,232 73,654
7.9 9.1 9.4 9.7
452,187 510,564 484,354 487,323
6.75 6.98 6.90 6.62
Table 3 NHI payments by groups from 2004 to 2009
2004 2005 2006 2007 2008 2009
NHI payments ($ million) 208.7 (100.0%) 228.9 (100.0%) 280.4 (100.0%) 329.8 (100.0%) 312.1 (100.0%) 334.3 (100.0%)
Gender
Male 134.3 (64.4%) 146.2 (63.8%) 182.5 (65.1%) 215.1 (65.2%) 204.0 (65.4%) 220.9 (66.1%)
Female 74.4 (35.6%) 82.8 (36.2%) 97.9 (34.9%) 114.7 (34.8%) 108.1 (34.6%) 113.5 (33.9%)
Age
<60 141.2 (36.3%) 80.2 (35.0%) 99.2 (35.4%) 114.4 (34.7%) 106.0 (33.9%) 112.4 (33.6%)
≥60 133.0 (63.7%) 148.8 (65.0%) 181.1 (64.6%) 215.4 (65.3%) 206.1 (66.1%) 221.9 (66.4%)
Type
Inpatient 175.5 (84.1%) 191.0 (83.4%) 235.8 (84.1%) 278.7 (84.5%) 261.8 (83.9%) 281.3 (84.1%)
Outpatient 33.2 (15.9%) 38.0 (16.6%) 44.5 (15.9%) 51.1 (15.5%) 50.3 (16.1%) 53.0 (15.9%)
Diagnosis
Myocardial infarction 132.0 (63.3%) 141.2 (61.7%) 171.2 (61.0%) 200.1 (60.7%) 193.8 (62.1%) 208.1 (62.2%)
Unstable angina 76.7 (36.7%) 87.8 (38.3%) 109.2 (39.0%) 129.7 (39.3%) 118.2 (37.9%) 126.2 (37.8%)
Medical institutions
Tertiary hospitals 122.6 (58.7%) 129.6 (56.6%) 149.1 (53.1%) 168.2 (51.0%) 156.2 (50.0%) 173.7 (52.0%)
General hospitals 65.0 (31.1%) 74.7 (32.6%) 102.0 (36.4%) 126.9 (38.5%) 122.0 (39.1%) 124.7 (37.3%)
Hospitals 2.1 (1.0%) 2.6 (1.1%) 3.3 (1.2%) 4.9 (1.5%) 5.3 (1.7%) 5.7 (1.7%)
Clinics 0.7 (0.3%) 0.8 (0.4%) 0.9 (0.3%) 1.2 (0.4%) 1.3 (0.4%) 1.4 (0.4%)
Pharmacy 18.4 (8.9%) 21.2 (9.3%) 25.1 (9.0%) 28.5 (8.6%) 27.3 (8.8%) 28.7 (8.6%)
Categories
Procedure and operation 70.6 (33.8%) 76.8 (33.6%) 94.9 (33.9%) 112.1 (34.0%) 105.3 (33.8%) 113.2 (33.9%)
Radiography 56.9 (27.3%) 62.0 (27.1%) 76.4 (27.3%) 90.2 (27.4%) 85.0 (27.3%) 91.3 (27.3%)
Pharmaceutical 24.3 (11.6%) 27.7 (12.1%) 33.1 (11.8%) 37.9 (11.5%) 36.2 (11.6%) 38.3 (11.4%)
Examination 22.1 (10.6%) 24.3 (10.6%) 29.5 (10.5%) 34.8 (10.5%) 33.3 (10.7%) 35.7 (10.7%)
Hospitalization 17.2 (8.2%) 18.7 (8.2%) 23.1 (8.2%) 27.3 (8.3%) 25.7 (8.2%) 27.6 (8.2%)
Others 17.6 (8.5%) 19.3 (8.4%) 23.4 (8.3%) 27.5 (8.3%) 26.6 (8.4%) 28.3 (8.5%)
Table 4 Societal costs of ACS from 2004 to 2009
2004 2005 2006 2007 2008 2009
Societal costs ($ million) 659.9 (100.0%) 718.1 (100.0%) 840.5 (100.0%) 880.6 (100.0%) 864.8 (100.0%) 918.2 (100.0%)
Direct costs 272.4 (41.2%) 299 (41.6%) 364.8 (43.4%) 435.7 (49.5%) 402.8 (46.6%) 436.7 (47.6%)
Medical costs 265.5 (40.2%) 291.2 (40.5%) 356.3 (42.3%) 425 (48.3%) 392.1 (45.4%) 425.3 (46.3%)
Inpatient 227.6 (34.5%) 248 (34.5%) 305.8 (36.3%) 366.6 (41.6%) 334.8 (38.7%) 357.5 (38.9%)
Outpatient 37.9 (5.7%) 43.2 (6.0%) 50.5 (6.0%) 58.4 (6.7%) 57.3 (6.7%) 67.8 (7.4%)
Non-medical costs 6.9 (1.0%) 7.8 (1.1%) 8.5 (1.1%) 10.6 (1.2%) 10.7 (1.2%) 11.4 (1.3%)
Transportation 4.2 (0.6%) 4.9 (0.7%) 5.5 (0.7%) 7.1 (0.8%) 7.2 (0.8%) 7.9 (0.9%)
Caregiving 2.7 (0.4%) 2.9 (0.4%) 3 (0.4%) 3.5 (0.4%) 3.4 (0.4%) 3.5 (0.4%)
Indirect costs 387.5 (58.8%) 419.1 (58.4%) 475.7 (56.6%) 444.9 (50.5%) 462 (53.4%) 481.5 (52.4%)
Lost wage due to morbidity 10.3 (1.6%) 11.9 (1.7%) 13.9 (1.7%) 16.7 (1.9%) 16.9 (2.0%) 16 (1.7%)
Lost future income 377.2 (57.2%) 407.3 (56.7%) 461.8 (54.9%) 428.2 (48.6%) 445.1 (51.4%) 465.6 (50.7%)
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over the six study years, from USD 659.9 million in 2004
to USD 918.2 million in 2009. Within the SCs associated
with ACS, the proportion for indirect costs ranged from
50.5% to 58.8% of the total NHI costs, which was higher
than the proportion for direct costs of between 41.2%
and 49.5% (Table 4).
The direct costs increased annually, except for 2008,
from USD 272.4 million in 2004 to USD 436.7 million in
2009. Within the direct costs associated with ACS, the
medical costs were estimated at USD 265.5 million in
2004, which was 40.2% of the 2004 total direct costs.
Medical cost increased annually and was USD 425.3 mil-
lion (46.3% of the total direct cost) in 2009. In addition,
the direct MC for hospitalization was USD 227.6 million
in 2004 and USD 357.5 million in 2009, approximately
six times that for outpatient MC. The 2004 non-medical
cost was approximately USD 6.9 million or 1.0% of the
total 2004 expenditures. The NMC increased annually
and was USD 11.4 million (1.3% of the total direct cost)
in 2009. Of the direct NMC associated with ACS, trans-
portation cost was USD 4.2 million in 2004, which in-
creased yearly to USD 7.9 million in 2009. Caregiving
cost was USD 2.7 million in 2004 and increased to USD
3.5 million in 2009 (Table 4).
The indirect cost in 2004 was USD 387.5 million,
58.8% of the total societal cost increasing to USD 481.5
million (52.4% of the total societal cost) in 2009. The in-
direct cost included lost wages of USD 10.3 million in
2004 and USD 16.0 million in 2009 and future lost in-
come of USD 377.2 million in 2004 and USD 465.5 mil-
lion in 2009 (Table 4).
Discussion
Our analysis was based on 2004–2009 NHI medical
claim data for the entire population in Korea. This data
source was used to examine ACS-related healthcare
utilization and associated expenditures in a real-world
setting over a period of years.
The results of this study indicate that the societal costs
associated with ACS are substantial. In Korea in 2005,
the COI of circulatory diseases, including ACS, was
13.1% of the total COI with circulatory diseases being
the second largest proportion of COI after that associ-
ated with neoplasms [1]. At the GDP level, the COI of
circulatory diseases in Korea is reported to be compar-
able to that in other countries [16-22]. In this study, the
indirect cost of ACS was approximately 55% of the total
NHI cost. This result is attributed to the age distribution
of the study population with the results showing high
morbidity and mortality in those aged below 70 years,
which is consistent with the results of other studies
[4,23]. However, the high percentage of indirect costs in
our study contrasts with the results of Johnston et al.[24]. The low proportion of indirect costs in the study
by Johnston et al. may be due to differences in the meas-
urement methods in the two studies; thus, it is difficult
to compare the two results.
Several studies have shown that a MI diagnosis is associ-
ated with higher NHI expenditures than those associated
with a diagnosis of UA [17,21]; results that are supported
by our findings. Additionally, our study shows that NHI
expenditures for procedures and operations including PCI
and CABG represent the highest proportion of the total
NHI cost, which supports the results of other studies on
ACS-associated costs [17,18,20,21,25]. Since several stud-
ies have suggested that interventional approaches (such as
PCI, stent, and CABG) reduce ACS-related morbidity and
mortality [26,27], NHI expenditures on such approaches
are likely to increase consistently. In this study, the NHI
hospitalization cost was six times that of the NHI out-
patient care cost. Moreover, NHI expenditures in tertiary
hospitals accounted for more than 50% of the total NHI
payments. Collectively, these findings indicate that ACS is
a societally important condition, one that requires appro-
priate treatment.
Over the study period, the number of patients with
ACS increased continuously from 217,297 in 2004 to
309,384 in 2009. Annually over that period, between
130,004 and 192,317 (approximately 60%) were men. As
with many other diseases, the prevalence of ACS in-
creases with age. In our study, approximately 50% of the
ACS patients were over the age of 60 years. The propor-
tion of ACS patients with UA was 44.9% in 2004, which
is lower than that of MI patients (55.1%). Over the study
period, the number of patients with UA increased more
sharply than that of MI patients and there were more
UA patients than MI patients in 2009.
20.2 and23.3 persons per 100,000 population mem-
bers, representing approximately 4% of the total deaths
and 17% of the cardiovascular disease deaths in Korea
[1]. While the prevalence of ACS increased over the
study period, the mortality rate decreased. This result
can be attributed to improvements in the early detection
and treatment of ACS. Although the elderly (those aged
over 70 years) had a high morbidity in this study, the
mortality rate in patients at a working age was also high.
This trend can lead to increased indirect costs, especially
those associated with future income. Of the patients in
this study who died due to ACS, MI was associated with
98% of the deaths. This is likely attributed to disease
progression of UA, which proceeds to MI with deterior-
ation. We found no other studies that showed a relation-
ship between ACS prevalence and subsequent mortality.
Over the study period, ACS-related hospital visits in-
creased for both outpatients and inpatients. Since the
outpatient visits increased more rapidly than that of the
inpatients, the outpatient-to-inpatient ratio increased
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charge after procedures such as PCI and coronary angi-
ography is feasible and safe [28-30]. Moreover, because of
factors such as patient satisfaction, medical costs, and
waiting lists the prevalence of same-day discharge is in-
creasing. Accordingly, that trend is likely to have affected
the outpatient-to-inpatient ratio in this study. While the
outpatient visits continued to increase during our study,
inpatient days decreased consistently from 7.18 days in
2004 to 6.62 days in 2009. This decrease is less than that
reported by others [16,18], except for a study conducted
in the United States [16,18,20,25]. Country specific differ-
ences in inpatient day results have been attributed to the
country’s type of healthcare system.
Limitation
This study has several limitations related to measuring
costs. First, we included only the cost of caregiving that
was provided by paid caregivers. To calculate caregiv-
ing costs more accurately, the cost of the informal care
provided by relatives should also be included. To that
end, information on relatives’ characteristics such as
gender, age, and occupation is required. Because of in-
sufficient information on the characteristics of the
caregivers we were unable to include costs related to
informal care. Second, we were unable to estimate
some items because of data restrictions and objective
quantification difficulties. For example, the cost for emer-
gency services and the intangible costs such as those re-
lated to pain and emotional anxiety due to ACS were
excluded from the study. Third, notwithstanding uncer-
tainties about the data, no sensitivity analysis to test the
robustness of our results was performed. If such limita-
tions are addressed in a future study, more accurate mea-
surements of SC of ACS could be achieved.
Conclusion
This 2004 to 2009 study showed that the number of pa-
tients with ACS in Korea has sharply increased and that
the societal cost of ACS in Korea is markedly high. ACS is
likely to remain a leading cause of hospitalization, due to
the aging Korean population and because of an increase in
risk factors for coronary heart disease. It is expected that
the proportion of the Korean population that is aged
65 years and older, and therefore at a high risk of ACS, will
increase until 2030. Thus ACS will continue to be a major
healthcare disease in the near future. This, coupled with
the continued presence of high risk factors associated with
ACS (such as obesity and diabetes) suggests that early and
effective management of ACS is required to reduce ACS-
related mortality and morbidity. Hence, significant public
and private healthcare resources will continue to be re-
quired to prevent and treat ACS. The findings of this
study suggest that further research should be undertakento discover ways to reduce the economic effects of ACS
on the Korean population.
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